Laurus Labs shareholding pattern

·Pharma & HealthChart ›

Who owns itSep 2026 quarter

Promoters27.47%no change
Foreign investors (FII)30.84%+2.84 pts
Domestic institutions (DII)11.86%−1.88 pts
of which mutual funds8.26%−1.89 pts
of which insurance companies2.35%
Public29.83%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LAURUSLABS₹2,244.00

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.21L Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group27.1827.1827.6227.6227.5927.5927.4927.4927.4727.47
FII / FPI25.6726.0825.5625.5225.7026.1626.5225.8228.0030.84
DII13.5613.0512.7411.7711.9411.7312.4313.9713.7411.86
Mutual Funds9.188.257.626.887.788.539.4911.2210.158.26
Latest: 2026-09-30 · 41 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.